- Learn the basics
- Find stocks
- Understand a stock
- Compare with peers
Alvotech
ALVO Luxembourg NASDAQAlvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
In short
Loading the key numbers…
What the sector means for this company
These sentences describe the numbers; they are not a recommendation. This content is not investment advice.
Price chart: each candle shows one day's opening, highest, lowest and closing price. The projection line is our model's estimate - a model, not a promise.
Price chart
The bars show each projection's high and low scenario. The more likely an outcome, the more solid its half of the bar: for the DCF, how often 400 simulations of the company's growth and margins reach that scenario; for the growth plans, up means the plans succeed and no expected decline hits, down means the plans fail and the declines hit. Switch them off with Ranges.
Key statistics: the most used ratios in one place. Tap the icon next to a name for a short explanation. Compare them with similar companies, not with the whole market.
Financial statements: the income statement shows sales and profit, the balance sheet what the company owns and owes, and the cash flow statement the money that actually came in and went out. How to read them.
Company policy and leadership: an AI-assisted assessment of how the company sells, executes, uses its resources and treats people, production and service. Read it as a starting point for your own research.
News: the latest articles about the company, grouped by day. Each has ratings for the outlet's stance towards the company, how factual it is and the market mood it conveys (an animal label such as Bull or Bear - hover it for the meaning). What the ratings mean.
More Health Care stocks
- Allarity Therapeutics, Inc. (ALLR)
- Allogene Therapeutics, Inc. (ALLO)
- Allurion Technologies, Inc. (ALUR)
- Alnylam Pharmaceuticals, Inc. (ALNY)
- Alpha Cognition Inc. (ACOG)
- Alpha Pro Tech Ltd (APT)
- Alpha Teknova, Inc. (TKNO)
- Alphatec Holdings, Inc. (ATEC)
- Alterity Therapeutics Ltd (ATHE)
- Altimmune, Inc. (ALT)
- Alto Neuroscience, Inc. (ANRO)
- Alumis Inc. (ALMS)
- Alx Oncology Holdings Inc (ALXO)
- Alzamend Neuro, Inc. (ALZN)
- Amarin Corp Plc\Uk (AMRN)
- American Shared Hospital Services (AMS)
- Amgen Inc (AMGN)
- Amicus Therapeutics, Inc. (FOLD)
- Amneal Pharmaceuticals, Inc. (AMRX)
- Amphastar Pharmaceuticals, Inc. (AMPH)
- Amylyx Pharmaceuticals, Inc. (AMLX)
- AN2 Therapeutics, Inc. (ANTX)
- Anaptysbio, Inc (ANAB)
- Anavex Life Sciences Corp. (AVXL)